Aging Muscle Sample Clauses

Aging Muscle. 6 1.2 Nucleocytoplasmic transport 8 1.2.1 Nuclear envelope 9 1.2.2 Nuclear pore complex 11 1.2.3 Nuclear transport receptors 17 1.3 Multinucleated cells 20 1.3.1 Multinucleated single-celled organisms 21 1.3.2 Multinucleated cells in multicellular organisms 23 1.4 Summary 30
Aging Muscle. Starting around age 30 in humans, muscle mass and strength begin an overall decline, and the rate of decline increases rapidly after age 60 (Metter, Conwit et al. 1997, Bassey 1998, Frontera, ▇▇▇▇▇▇ et al. 2000). The loss of muscle mass and strength results from hypoplasia (loss of muscle cells) and atrophy (reduction in the size of the remaining muscle cells). In addition, motor units undergo a switch from fast motor units to slow motor units (▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇ et al. 1973), increasing delays in reaction time and increasing the risk of loss of balance and falls. Decreased muscle function increases morbidity and decreases quality of life for the elderly. Reduced muscle strength is associated with reduced mobility (▇▇▇▇▇, Rejeski et al. 2011, ▇▇▇▇▇▇, ▇▇▇▇▇▇ et al. 2013) and greater risk of falls (Cesari, Kritchevsky et al. 2005, ▇▇▇▇▇, ▇▇▇▇▇▇▇▇ et al. 2012) and disability (▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇ et al. 2006, Xue, ▇▇▇▇▇▇▇ et al. 2011). The functional and physiological changes in aging muscle are accompanied by changes in the transcriptome and epigenome. mRNA levels are altered in aging: transcripts related to metabolism are depleted in older muscle, while transcripts related to inflammation and damage response are enriched (▇▇▇▇, ▇▇▇▇ et al. 2006, ▇▇▇, Park et al. 2014, Su, Ekman et al. 2015). These changes reflect functional changes like myofiber type switching. ▇▇▇▇▇ expression and DNA methylation also change with age. Levels of miRNAs regulating transcripts involved in transcription and differentiation are altered (▇▇▇, Park et al. 2014). Aging is also correlated with global DNA hypermethylation (▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇ et al. 2014). While there are established connections between altered gene expression and the loss of muscle mass and function, the molecular mechanisms driving a shift in gene expression remain elusive. The changes in transcript levels with age are also accompanied by proteomic changes in aging muscle. Approximately 10% of proteins in rat skeletal muscle change significantly with age (▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇ et al. 2009). Most age-associated changes in human and rodent skeletal muscle are detected in contractile and metabolic proteins (Baraibar, Gueugneau et al. 2013, Holland, ▇▇▇▇▇▇▇ et al. 2014). Sarcomeric and metabolic proteins are orders of magnitude more abundant than other proteins in the tissue, so these proteins dominate any proteomic analysis to the exclusion of low abundance proteins. In mouse and human samples ~50% of proteins identified and ~80...

Related to Aging Muscle

  • Hepatitis B Vaccine Where the Hospital identifies high risk areas where employees are exposed to Hepatitis B, the Hospital will provide, at no cost to the employees, a Hepatitis B vaccine.

  • How to get a TIN If you do not have a TIN, apply for one immediately. To apply for an SSN, get Form SS-5, Application for a Social Security Card, from your local SSA office or get this form online at ▇▇▇.▇▇▇.▇▇▇. You may also get this form by calling ▇-▇▇▇-▇▇▇-▇▇▇▇. Use Form W-7, Application for IRS Individual Taxpayer Identification Number, to apply for an ITIN, or Form SS-4, Application for Employer Identification Number, to apply for an EIN. You can apply for an EIN online by accessing the IRS website at ▇▇▇.▇▇▇.▇▇▇/▇▇▇▇▇▇▇▇▇▇ and clicking on Employer Identification Number (EIN) under Starting a Business. Go to ▇▇▇.▇▇▇.▇▇▇/▇▇▇▇▇ to view, download, or print Form W-7 and/or Form SS-4. Or, you can go to ▇▇▇.▇▇▇.▇▇▇/▇▇▇▇▇▇▇▇▇▇ to place an order and have Form W-7 and/or SS-4 mailed to you within 10 business days. If you are asked to complete Form W-9 but do not have a TIN, apply for a TIN and write “Applied For” in the space for the TIN, sign and date the form, and give it to the requester. For interest and dividend payments, and certain payments made with respect to readily tradable instruments, generally you will have 60 days to get a TIN and give it to the requester before you are subject to backup withholding on payments. The 60-day rule does not apply to other types of payments. You will be subject to backup withholding on all such payments until you provide your TIN to the requester.

  • Vlastnictví Zdravotnické zařízení si ponechá a bude uchovávat Zdravotní záznamy. Zdravotnické zařízení a Zkoušející převedou na Zadavatele veškerá svá práva, nároky a tituly, včetně práv duševního vlastnictví k Důvěrným informacím (ve smyslu níže uvedeném) a k jakýmkoli jiným Studijním datům a údajům.

  • Publikace The Institution and the Investigator agree that the Sponsor shall have the sole and exclusive right to the first publication of the results of the Study. Such Sponsor publication is intended to be a multi-center publication of the Study results, collected from all investigators and institutions participating in the Study (the “Multi- Center Publication”). If the Investigator is interested in contributing to or participating in the Multi-Center Publication, he or she must contact the Sponsor. Selection of authors/participants will be governed by the Sponsor, considering individuals’ contribution to the Study.

  • DUŠEVNÍ VLASTNICTVÍ The Institution and the Investigator acknowledge and agree that the Sponsor shall have exclusive ownership rights to all Study Data, improvements, developments, discoveries, inventions, work, know- how and other rights (whether or not patentable), created, developed, and/or reduced to practice as a result of or in connection with the conduct of the Study and/or the use of the Study Drug or the Confidential Information, together with all intellectual property rights relating thereto (“Intellectual Property”). The Institution and the Investigator shall promptly disclose in writing to the Sponsor all Intellectual Property made by the Institution, the Investigator and/or the Study Personnel. At the Sponsor's request, the Institution and the Investigator shall cause all rights titles and interests in and to any such Intellectual Property to be assigned to the Sponsor without additional compensation and provide reasonable assistance to obtain patents, including causing the execution of any invention assignment or other documents. In case, for legal or factual reasons, the Institution and Zdravotnické zařízení a Hlavní zkoušející uznávají a souhlasí, že Zadavatel bude mít výhradní vlastnická práva ke všem Studijním údajům, vylepšením, na vývoj, k objevům, vynálezům, dílům, know-how a dalším právům (ať už patentovatelným či nikoli), vytvořeným, vyvinutým, a/nebo uvedeným do praxe v důsledku nebo v souvislosti s prováděním Studie, a/nebo používáním Studijního léku nebo Důvěrných informací společně s právy duševního vlastnictví s nimi souvisejícími (dále jen „Duševní vlastnictví“). Zdravotnické zařízení a Hlavní zkoušející budou neprodleně písemně informovat Zadavatele o veškerém Duševním vlastnictví vytvořeném Zdravotnickým zařízením, Hlavním zkoušejícím a/nebo Studijním personálem. Na žádost Zadavatele zajistí Zdravotnické zařízení a Hlavní zkoušející převod veškerých práv a zájmů týkajících se Duševního vlastnictví na Zadavatele bez další odměny a poskytnou přiměřenou součinnost k získání patentu včetně zajištění podpisu dokumentů k převodu objevu nebo jiných dokumentů. V případě, kdy z právních nebo the Investigator can’t cause all rights titles and interests in and to any such Intellectual Property to be assigned to the Sponsor, they shall provide the Sponsor with a royalty free license to the same extend. věcných důvodů Zdravotnické zařízení a Hlavní zkoušející nebudou moci zajistit převedení všech vlastnických práv a zájmů týkajících se Duševního vlastnictví na Zadavatele, jsou povinni poskytnout ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇.